Coloverin D tablets composition:
Each film coated tablet contains:
Mebeverine HCL 135 mg.
Coloverin D tablets properties:
Mebeverine hydrochloride is a musculotropic spasmolytic with a strong and selectiveaction on the smooth muscle spasm of the gastrointestinal tract, particularly of the colon. Dimethicone is a gastrointestinal protective agent with antifoaming action. It is used in the treatment of problems due to excess gastrointestinal gases such as flatulence and abdominal discomfort.
Coloverin D Tablets Indications:
Treatment of functional bowel disorders such as:
– Irritable bowel syndrome
– Abdominal pains
– Distension and dyspepsia
– Postoperative gas pains
Coloverin D tablets dosage:
One tablet 3 or 4 times daily, preferably 20 minutes before meals.
Coloverin D tablets contraindications:
Hypersensitivity to any component of the product.
Coloverin D tablets side effects:
No adverse effects attributable to mebeverine hydrochloride or dimethicone have been reported.
Strips, each contains 10 tablets.
Store below 30· C.
Chemipharm Pharmaceutical Industries
6th October City – Egypt
Irritable bowel syndrome PPT power point presentation :
1. Irritable Bowel Syndrome Dr Junaid Saleem
2. Conflict of Interest Statement • Sponsored by Abbott for this lecture • No other conflicts of interest 2
3. Short Version • Irritable Bowel Syndrome – Definition? – Aetiology? – Pathology? – Clinical Features – Diagnosis? – Treatment? – Prognosis +/- 3
4. Introduction • First described in 1771. • 50% of patients present <35 years old. • 70% of sufferers are symptom free after 5 years. • GPs will diagnose one new case per week. • GPs will see 4-5 patients a week with IBS. • Point prevalence of 40-50 patients per 2000 patients. 4
5. What Is IBS? • A syndrome. • One man’s constipation is another man’s normality. • Cause unknown. • 20% seem to start after an episode of gastroenteritis. 5
6. Psychosocial factors •IBS aetiology is multi-factorial •Emotions significantly affect colonic response in IBS – Stressful stimuli disrupt upper GI motility in several ways, including mean • oesophageal peristaltic amplitude, • rate of gastric emptying, • small bowel transit, and • increased upper oesophageal sphincter pressure Aetiology
7. Psychosocial factors •The response to stress is mediated by corticotrophin releasing factor (CRF) secreted by the enteric neurons, enteroendocrine cells and immune cells – CRF binds to CRF receptors present on smooth muscle cells and increase the number of discrete cluster contractions – Psychosocial factors exacerbate the symptoms of IBS but a definite link has not been established Aetiology
9. • Exact pathophysiology remains uncertain • Dysregulation within the brain gut axis, • interactions between genetics, • psychosocial factors, • post-inflammatory changes and • motor and sensory dysfunction are all likely to influence the development of IBS Pathophysiology Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-1798. Mawe GM, Coates MD, Moses PL. Intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1067-1076.
10. • Exact pathophysiology remains uncertain • Visceral hypersensitivity – enhanced pain sensitivity of the gut – may play an important role in the development of chronic pain and discomfort in IBS1 • Heightened sensitivity of the peripheral nervous system is caused by immune and inflammatory mediators acting at the site of tissue injury and inflammation Pathophysiology Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-1798. Mawe GM, Coates MD, Moses PL. Intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1067-1076.
11. • Exact pathophysiology remains uncertain • Serotonin (5-HT) – present extensively in the GI tract – is the most important neurotransmitter in the pathogenesis of IBS, • peripheral sensitisation causes an area of hypersensitivity to develop in the surrounding uninjured tissue – this phenomenon is called central sensitisation Pathophysiology Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-1798. Mawe GM, Coates MD, Moses PL. Intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1067-1076.
12. Disturbances in GI motility •A proportion of IBS patients, specifically those reporting constipation or dyspeptic symptoms, exhibit delayed gastric emptying, especially of solids, this correlates with absence of post-prandial increase in electrogastrography (EGG) amplitude Pathophysiology Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol 2008;14(17):2639-2649.